Key Stats for Danaher Stock
- Past-Week Performance: -10%
- 52-Week Range: $161 to $243
- Valuation Model Target Price by the End of 2028: Around $245
- Implied Upside: Around 37%
Analyze your favorite stocks like Danaher Corporation with TIKR (It’s free) >>>
What Happened?
Danaher faces a central Wall Street question: Can recovering bioprocessing demand translate into revenue quickly enough to restore growth and margins? That debate turned sharply bearish after Danaher closed near $179, falling 11% on Tuesday and around 10% over the past week.
Danaher stock fell because several large commercial customers postponed more than $100 million of bioprocessing shipments into 2027, leading management to reduce its 2026 growth expectations despite an earnings beat. Second-quarter revenue increased 5.5% to $6.3 billion, while adjusted EPS rose 8% to $1.94 and exceeded the $1.84 consensus estimate. However, Biotechnology core revenue grew only 2.5%, prompting Danaher to narrow its full-year core revenue growth outlook to 3% to 4% from 3% to 6% and forecast 2% to 3% growth for the third quarter.
Bioprocessing covers the equipment and consumable materials drugmakers use to manufacture biological medicines. The delayed shipments primarily involved chromatography resins, which are materials used to purify these medicines during production. Core revenue removes the effects of acquisitions and currency movements to show the underlying performance of Danaher’s businesses.
CEO Rainer Blair said, “While customer project timing impacted bioprocessing revenue, underlying order trends remained strong,” adding that bioprocessing orders grew at a mid-teens rate. Life Sciences core revenue increased 5.5%, while Masimo adds devices that measure blood-oxygen levels and other hospital patient-monitoring products. Better quarterly performance and the earlier Masimo closing helped Danaher raise its full-year adjusted EPS guidance to $8.45 to $8.60 from $8.35 to $8.55.
Competitor results help explain why Danaher’s bioprocessing performance disappointed investors. In their latest reported quarters, broad life-sciences competitor Thermo Fisher Scientific generated 1% companywide organic revenue growth, while direct bioprocessing competitor Sartorius reported 8.1% constant-currency growth in Bioprocess Solutions. The reporting periods and business mixes differ, but Sartorius’s stronger growth provides a useful benchmark against Danaher’s 2.5% Biotechnology core growth.
Analyst reactions reflected uncertainty about the recovery. Baird raised its Danaher price target to $251 from $245 before earnings, while Evercore ISI lowered its target to $205 from $230 after the report and RBC increased its target to $215 from $200. As TIKR previously highlighted, Danaher’s recovery depends on bioprocessing orders converting into revenue, and the latest results show that timing remains the central uncertainty.
Value Danaher Corporation instantly (Free with TIKR) >>>
Is Danaher Stock Undervalued?
Under the valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): Around 8%
- EBIT Margin: Around 29%
- Exit P/E Multiple: Around 22x
Analysts expect Danaher’s EBIT margin to improve from around 28% in 2025 to around 30% by 2030.
The model’s 8% revenue-growth assumption exceeds Danaher’s 3% to 4% core growth outlook for 2026 because it captures Masimo’s acquisition contribution and assumes the delayed bioprocessing shipments begin contributing in 2027. This makes the model a recovery scenario rather than a conservative base case.
See analysts’ growth forecasts and price targets for Danaher Corporation (It’s free) >>>
The 29% EBIT margin assumption is supported by analyst estimates showing the margin approaching 30% by 2030. Achieving that expansion would still require higher bioprocessing volumes, recurring consumables growth, successful Masimo integration, and productivity improvements from the Danaher Business System, the company’s framework for improving productivity, pricing, and innovation.
At around $179, Danaher trades near 21x the midpoint of management’s 2026 adjusted EPS guidance. The 22x exit P/E therefore assumes only modest valuation expansion and no return to the premium multiples Danaher commanded during the pandemic-era life-sciences boom.
Based on these assumptions, the model estimates that Danaher stock could reach around $245 by the end of 2028. That represents around 37% total upside, or an annualized return of around 14%, from its latest closing price near $179.
Over the next 12 months, the most important driver will be whether Danaher converts its mid-teens bioprocessing order growth into revenue. Continued Life Sciences growth would provide another source of support. Masimo must also be integrated without weakening Danaher’s margins. Further shipment delays would make the model’s 8% growth assumption difficult to achieve. Under this recovery scenario, Danaher appears undervalued, but the company still needs to prove that its Biotechnology weakness reflects customer timing rather than deteriorating demand.
How Much Upside Does DHR Stock Have From Here?
Investors can estimate Danaher Corporation’s potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
Value Danaher Corporation in under 60 seconds with TIKR (It’s free) >>>
